Bifalgorithm post · 10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 1. Etcamah for ESR1-Mutated Breast Cancer

Etcamah Approval

Etcamah Approval (10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 1. Etcamah for ESR1-Mutated Breast Cancer) — "Etcamah (camizes…

Ideas in this flowchart

  • Etcamah (camizestrant) in advanced breast cancer
  • It is taken with a CDK4/6 inhibitor.
  • It is for HR-positive, HER2-negative advanced breast cancer.
  • Eligibility requires a blood test finding an ESR1 mutation during first-line treatment, before scans show growth.
  • The SERENA-6 trial evaluated switching treatment after this finding.
  • People who switched had a median of 16 months before their cancer progressed.
  • People who did not switch had a median of 9.2 months before their cancer progressed.
  • CURE first covered the trial when results showed that the switch delayed progression.
Bifalgorithm
Sign up
Feed/

Etcamah Approval

No cover

Channel

10 Cancer Treatment Approvals From September 2026 and What They Mean for You

1 page

U
USR292600b83e2a
Ebook2w

"Etcamah (camizestrant), taken with a CDK4/6 inhibitor, is for HR-positive, HER2-negative advanced breast cancer when a blood test finds an ESR1 mutation during first-line treatment, before scans show growth. In the SERENA-6 trial, people who switched went a median of 16 months before their cancer progressed, vs 9.2 months for those who didn't. CURE first covered the trial when results showed the switch delayed progression."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.